Mu Opioid Receptor 1 Protein (Myc-DYKDDDDK Tag)

Produktnummer ABIN2727919

Produktdetails

Target: Mu Opioid Receptor 1 (OPRM1) (Opioid Receptor, mu 1 (OPRM1))

Protein-Typ: Recombinant

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses Mu Opioid Receptor 1 Protein ist gelabelt mit Myc-DYKDDDDK Tag.

Applikation: Antibody Production (AbP), Standard (STD)

Produktmerkmale:

• Recombinant human OPRM1 (transcript variant MOR-1) protein expressed in HEK293 cells.
• Produced with end-sequenced ORF clone

Reinheit: > 80 % as determined by SDS-PAGE and Coomassie blue staining

Anwendungsinformationen

Applikationshinweise: Recombinant human proteins can be used for:
Native antigens for optimized antibody production
Positive controls in ELISA and other antibody assays

Kommentare:

The tag is located at the C-terminal.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 50 μg/mL

Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.

Lagerung: -80 °C

Informationen zur Lagerung: Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Antigendetails

Target: Mu Opioid Receptor 1 (OPRM1) (Opioid Receptor, mu 1 (OPRM1))

Andere Bezeichnung: Oprm1 (OPRM1 Produkte)

Synonyme: LMOR Protein, M-OR-1 Protein, MOP Protein, MOR Protein, MOR1 Protein, OPRM Protein, MOP-R Protein, MOR-1 Protein, MOR-1O Protein, Oprm Protein, mor Protein, muOR Protein, MORA Protein, Oprrm1 Protein, or2 Protein, ZFOR2 Protein, OPRM1 Protein, opioid receptor mu 1 Protein, opioid receptor, mu 1 Protein, outer membrane protein OprM Protein, OPRM1 Protein, Oprm1 Protein, oprm1 Protein, oprM1 Protein

Hintergrund: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A [UniProtKB/Swiss-Prot Function]

Molekulargewicht: 44.6 kDa

NCBI Accession: NP_000905

Pathways: cAMP Metabolic Process, Synaptic Membrane